independence blue cross glp 1 to stop covering GLP-1 agonists Wegovy, Ozempic as weight loss drugs in 2025 BCBSM pulling back on GLP-1
Description
In a multicenter, randomized, double-blind, placebo-controlled phase 2 trial by NET-PD researchers, pioglitazone was evaluated for its effects on PD progression
Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Aon's GLP-1 study brings additional data points to employers looking to make the best decisions specific to their people strategy and population
[DOI] [PMC free article] [PubMed] [Google Scholar] 75.Little TJ, et al
"I'm talking about s--
A thorough explanation outlining why you think the treatment should be covered, citing any pertinent health conditions
Inflammatory markers decrease, potentially reducing vascular inflammation
